TCTR20170329002已完成3 期
The efficacy and safety of Andrographis paniculata extract for the treatment of acute nonspecific upper respiratory tract infections: a randomized double-blind placebo controlled trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 829
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •Adults aged 18 to 60 years old who attended the OPD clinics within 72 hours after the onset of URI symptoms and were diagnosed as acute NS-URI which had one or more symptoms such as fever, sore throat, nasal congestion, dry infrequent cough and had modified Centor Score of 2 or less. The patients could take the assigned medication and returned for the first follow up at days 4-7. They would be able to receive phone call for interviewing the illness and symptoms in the second follow-up at days 14-30 and signed the informed consent.
排除标准
- •1.Patients who have been diagnosed is an upper respiratory tract caused by bacterial infection.
- •1) High fever. (>38.3 °C)
- •2) Pustules found on the tonsils.
- •3) Lymph nodes in the neck> 1 cm or feeling sore from the neck at one side by palpation.
- •2.There is evidence that severe upper respiratory infections such as acute sinusitis, allergic rhinitis, influenza.
- •3.Shortness of breath / difficulty, difficulty speaking.
- •4.Has nausea, vomiting, diarrhea, hemorrhage or other severe symptoms.
- •5.Modified Centor score> 2. (Please specify ............)
- •à¸¸6.Has a history of rheumatic heart disease or nephritis, because it was attached Streptococcus group A.
- •7.Has a history of allergic Andrographis paniculata extract.
- •8.Have chronic liver or kidney disease from history of treatment and / or blood test results.
- •9. Pregnant or breastfeeding women.
- •10.Blood clotting medication is used. (Clopidogrel, warfarin, aspirin)
- •11.Within 48 hours after the onset of symptoms before seeing a doctor. Patient records that. Get antibiotics like amoxicillin, antibiotics, steroids or steroids, NSAIDs or other herbs.
- •12.The recipient immunosuppressant agents or chemotherapy.
- •13.The recipient organ transplantation.
研究者
相似试验
已完成
1 期
Efficacy and safety of Andrographis paniculata extract in patients with mild COVID-19: A randomized controlled trialTCTR20210708001Thai Traditional Medicine Knowlegde funding63
招募中
3 期
Efficacy and safety of Andrographis paniculata extract for the treatment of asymptomatic or mild-symptoms COVID-19 patients: A double-blinded, randomized-control trialCOVID-19 patienrs, RT-PCR confirmedCovid-19 treatmentAndrographidis paniculatae extractPneumoniaTCTR20211224002Health System Research Institute736
尚未招募
4 期
A clinical study to understand the combined effects of Andrographis & metformin, in comparison to metformin alone treatment on glycemic control in type 2 diabetes patientsCTRI/2019/11/021977Dr Anand Kumar Maurya
已完成
2 期
Comparison efficacy and safety of Andrographis paniculata extract capsules and placebo in COVID-19 patients: Double blind randomized control trialCOVID-19 patient with asymptomatic and mild symptomatic. Progression score between 0-3. (Green color)COVID-19AndrographolideTCTR20210809004Thammasat university186
已完成
2 期
Efficacy of Andrographis paniculata extract Combined with Favipiravir Treatment to Prevent Disease Progression in mild to moderate COVID-19 Patients: A Double-blind, Randomized, Placebo-Controlled StudyMild to moderate COVID-19andrographolides, COVID-19, SARS-CoV-2, andrographis panniculata, favipiravirTCTR20210609001Chulabhorn Royal Academy146